A Free-Market Path Forward in Louisiana’s PBM Debate
The debate over pharmacy benefit managers (PBMs) in Louisiana continues, with lawmakers advancing legislation aimed at lowering prescription drug costs and protecting independent pharmacies. At the center of this debate is House Bill 919, a wide-ranging proposal that initially included a prohibition on vertical integration between PBMs, insurers, and pharmacies. While these goals are understandable, the growing trend toward aggressive state intervention risks repeating a familiar pattern: well-intentioned policies that ultimately distort markets, reduce competition, and raise costs for consumers.
Encouragingly, lawmakers have already taken an important step in the right direction. The House Committee on Health and Welfare’s decision to remove the prohibition on vertical integration from HB 919 as it advanced reflects a recognition that not every perceived issue requires a sweeping ban. Preserving flexibility in how companies structure their operations allows the market to function more effectively and helps avoid eliminating efficiencies that can benefit consumers. This course correction should be applauded and serve as a model for how to approach the broader PBM debate.
PBMs play a complex but important role in the healthcare system. As intermediaries, they negotiate drug prices, manage formularies, and administer prescription drug benefits for insurers and employers. Critics argue that PBMs contribute to high drug prices through opaque practices like spread pricing and rebate structures, and these concerns have driven both litigation and legislative action in Louisiana and across the country. But focusing solely on PBMs risks oversimplifying a far more complicated pharmaceutical supply chain—one in which manufacturers, insurers, and regulators all play a role in determining costs.
In Louisiana, the policy response has increasingly leaned toward increased regulation. Lawmakers have proposed requiring PBMs to reimburse pharmacies at fixed rates, imposing minimum dispensing fees, and restricting business models such as vertical integration. HB 919 itself sparked intense debate, with supporters arguing it would protect independent pharmacies, while opponents warned it could disrupt access and increase costs.
From a free-market perspective, the problem is not that reform is being pursued, but how it is being pursued. When government dictates pricing structures or prohibits certain business arrangements, it replaces voluntary exchange with regulatory mandates. This often produces unintended consequences. For example, setting reimbursement floors or dispensing fees may help some pharmacies in the short term, but it can also increase overall costs, which are ultimately passed on to employers, taxpayers, and patients through higher premiums or reduced access.
Similarly, proposals to ban or restrict vertical integration—where PBMs, insurers, and pharmacies operate under the same umbrella—risk eliminating efficiencies that can benefit consumers. While concerns about conflicts of interest are valid, outright prohibitions ignore the potential for integrated models to streamline operations and reduce costs. A better approach is toallow these models to compete in the marketplace, where employers and consumers can determine which arrangements deliver the best value.
This is where free-market principles offer a more sustainable path forward. Rather than attempting to micromanage the pharmaceutical supply chain, policymakers should focus on empowering consumers and purchasers with better information. Increased transparency around pricing, rebates, and fees would allow employers and health plans to make more informed decisions when selecting PBMs. At the same time, removing barriers to entry for new PBM models—including pass-through or transparent PBMs—would foster competition and innovation.
It is also important to recognize the broader risks of continued intervention. Each new layer of regulation creates a “slippery slope” in which government becomes increasingly involved in private markets, often leading to calls for even more intervention when initial policies fail to deliver expected results. Over time, this can transform a competitive marketplace into a heavily regulated system with fewer choices and higher costs.
The stakes are not just theoretical. Louisiana has already seen legal battles emerge over PBM-related policies, and further aggressive regulation could invite additional litigation—costing taxpayers time and money while creating uncertainty for patients and providers. Meanwhile, evidence from other states suggests that heavy-handed reforms do not always produce the intended savings and can sometimes exacerbate the very problems they seek to solve.
A free-market approach does not mean ignoring concerns about PBMs. It means addressing them in a way that preserves competition, encourages innovation, and respects consumer choice. Policymakers should prioritize transparency, enforce existing laws against fraud and anticompetitive behavior, and allow market forces to discipline bad actors. This approach recognizes that sustainable solutions are more likely to emerge from competition than from mandates.
As the debate continues, Louisiana policymakers should remain grounded in tried-and-true free-market principles. The Legislature’s decision to remove the vertical integration prohibition from HB 919 demonstrates that thoughtful revisions are possible and that balance can be achieved. By resisting the urge to overregulate and instead fostering transparency and competition, the state can pursue lower drug costs without sacrificing innovation or access. The goal should not be to pick winners and losers in the healthcare marketplace, but to create an environment where consumers, employers, and providers are free to choose—and where better outcomes can emerge naturally from that freedom.
